Scholarlink

Background <p>Patients with colorectal cancer (CRC) undergoing systemic therapy frequently experience functional decline, fatigue, and treatment-related symptoms. Resistance training (RT) is safe during treatment, but the minimum effective duration remains unclear.</p> Objective <p>To compare the effects of an 8-week versus 12-week supervised RT program on chemotherapy-induced peripheral neuropathy (CIPN) and selected functional, psychosocial, behavioral, and hematological/inflammatory parameters in patients with CRC.</p> Methods <p>In this pilot randomized clinical trial, 30 adults with CRC were randomized (1:1) to 8 weeks (<i>n</i> = 15) or 12 weeks (<i>n</i> = 15) of supervised RT (2 sessions/week) plus home-based physical activity (3 days/week). The primary outcome was CIPN (EORTC QLQ-CIPN20). Secondary outcomes included handgrip strength, quality of life (EORTC QLQ-C30), anxiety/depression (HADS), physical activity, and hematological/inflammatory parameters.</p> Results <p>All participants completed the intervention, with adherence &gt; 90% and no adverse events. No between-group differences were observed in CIPN. Handgrip strength suggested greater adjusted gains in the 12-week group for both dominant (pFDR = 0.026) and non-dominant hand (pFDR = 0.009). Psychological outcomes showed an adjusted between-group difference for HADS total score (pFDR = 0.022). Exploratory analyses suggested a reduction in NLR after 12 weeks (<i>p</i> = 0.043), with no significant adjusted between-group differences. Nominal between-group differences in fatigue and gastrointestinal symptoms were observed only in unadjusted analyses.</p> Conclusions <p>Supervised RT during systemic treatment in CRC appears feasible and safe. In this pilot dose-comparison trial, both programs were associated with improvements in selected outcomes, although efficacy cannot be established. A 12-week duration may be associated with additional benefits; however, findings are exploratory. Larger trials including usual-care controls are needed.</p> Registration <p>The clinical trial was registered in ClinicalTrials.gov (NCT07307690) on 1 January 2026.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

8- versus 12-week supervised resistance training with home-based physical activity during colorectal cancer treatment: a pilot randomized dose-comparison trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Carlos Martín-Sánchez,
  • Luis Polo-Ferrero,
  • Roberto Méndez-Sánchez,
  • Ana Silvia Puente-González,
  • Tamara Manso-Hierro,
  • Eduardo José-Fernández-Rodríguez,
  • Nuria Arroyo-Garrapucho,
  • Yolanda López-Mateos,
  • Sofia Lorena Espinal-Matos,
  • Emilio Fonseca-Sánchez,
  • Lorena Medina Hernández,
  • Manuel Fuentes,
  • Juan Luis Sánchez-González

摘要

Background

Patients with colorectal cancer (CRC) undergoing systemic therapy frequently experience functional decline, fatigue, and treatment-related symptoms. Resistance training (RT) is safe during treatment, but the minimum effective duration remains unclear.

Objective

To compare the effects of an 8-week versus 12-week supervised RT program on chemotherapy-induced peripheral neuropathy (CIPN) and selected functional, psychosocial, behavioral, and hematological/inflammatory parameters in patients with CRC.

Methods

In this pilot randomized clinical trial, 30 adults with CRC were randomized (1:1) to 8 weeks (n = 15) or 12 weeks (n = 15) of supervised RT (2 sessions/week) plus home-based physical activity (3 days/week). The primary outcome was CIPN (EORTC QLQ-CIPN20). Secondary outcomes included handgrip strength, quality of life (EORTC QLQ-C30), anxiety/depression (HADS), physical activity, and hematological/inflammatory parameters.

Results

All participants completed the intervention, with adherence > 90% and no adverse events. No between-group differences were observed in CIPN. Handgrip strength suggested greater adjusted gains in the 12-week group for both dominant (pFDR = 0.026) and non-dominant hand (pFDR = 0.009). Psychological outcomes showed an adjusted between-group difference for HADS total score (pFDR = 0.022). Exploratory analyses suggested a reduction in NLR after 12 weeks (p = 0.043), with no significant adjusted between-group differences. Nominal between-group differences in fatigue and gastrointestinal symptoms were observed only in unadjusted analyses.

Conclusions

Supervised RT during systemic treatment in CRC appears feasible and safe. In this pilot dose-comparison trial, both programs were associated with improvements in selected outcomes, although efficacy cannot be established. A 12-week duration may be associated with additional benefits; however, findings are exploratory. Larger trials including usual-care controls are needed.

Registration

The clinical trial was registered in ClinicalTrials.gov (NCT07307690) on 1 January 2026.